Resonance soars on FDA approval

03/12/2018 - 15:23

Bookmark

Save articles for future reference.

Shares in Resonance Health have doubled today after its FerriSmart technology, which uses machine learning to quantify liver iron concentration, received FDA approval.

FerriSmart automatically analyses MRI images.

Shares in Resonance Health have doubled today after its FerriSmart technology, which uses machine learning to quantify liver iron concentration, received FDA approval.

Burswood-based Resonance said it had received clearance from the US Food and Drug Administration, allowing the company to market and distribute the technology in the US.

FerriSmart automatically analyses MRI images from most scanner makes and models, and returns a liver iron quantification result within seconds.

The FDA has cleared FerriSmart to measure liver iron concentration in individuals with confirmed or suspected systemic iron overload, monitor liver iron burden, and aid in the identification and monitoring of non-transfusion-dependent thalassemia patients receiving therapy with deferasirox.

“This clearance allows Resonance Health to market FerriSmart for commercial distribution in the US,” the company said in a statement to the ASX.

“Deploying FerriSmart via channel partner platforms such as the Blackford Platform allows FerriSmart to integrate seamlessly into radiology workflows, delivering results efficiently to radiologists and clinicians.

“The company looks forward to continuing to provide clinicians and patients with outstanding image analysis products.”

Resonance shares finished ahead 100 per cent at 5.2 cents each today, which was their highest mark since 2014.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options